Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Sam Samad is Executive Vice President & CFO at Quest Diagnostics. OQRO lists 13 transactions filed with the SEC under this name, the latest on Oct 23, 2026, each linked to the official Form 4.
Executive Vice President & CFO
Disclosures on record
13
Companies involved
2
Sam Samad has no open-market purchase on record since 2019. Sales in 2 of the 8 years since 2019.
Sam Samad reported 0 open-market purchases and 7 sales since 2019; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2020 | — | $2.04M6×6 trades |
| 2019 | — | $285K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Quest DiagnosticsDGX
11 disclosures · Feb 2026 – Oct 2026
Oct 21, 202690disclosed Oct 23
DetailsOfficial recordJul 22, 2026102disclosed Jul 27
DetailsOfficial recordApr 20, 2026108disclosed Apr 24
DetailsOfficial recordMar 4, 202614Kdisclosed Mar 6
DetailsOfficial recordMar 4, 20267,720disclosed Mar 6
DetailsOfficial recordMar 2, 2026869disclosed Mar 4
DetailsOfficial recordFeb 18, 20263,965disclosed Feb 20
DetailsOfficial recordJan 28, 202669disclosed Feb 20
DetailsOfficial recordFeb 18, 202618Kdisclosed Feb 20
DetailsOfficial recordFeb 18, 2026855disclosed Feb 20
DetailsOfficial recordFeb 18, 20261,010disclosed Feb 20
DetailsOfficial recordIdexx LaboratoriesIDXX
2 disclosures · May 2026
May 12, 2026525disclosed May 14
DetailsOfficial recordMay 12, 2026234disclosed May 14
DetailsOfficial recordAs of the latest filing on , Sam Samad reported holding 33,568 shares of Quest Diagnostics (DGX), worth about $8.7M at the last close of $259 (Nov 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Quest Diagnostics DGX | 33,568 | 34K direct | $259 | $8.7M | Oct 21, 2026 |
Is this Sam Samad’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Sam Samad reported 0 open-market purchases and 7 sales here, 2019 to 2020.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Oct 21, 2026, Sam Samad reported holding 33,568 shares of Quest Diagnostics (DGX). At the last close of $259 on Nov 19, 2026, that is about $8.7M. This is the stake disclosed in filings, not a net worth.
No public filing gives Sam Samad's net worth. What SEC Form 4 shows is the stock stake: 33,568 shares of Quest Diagnostics (DGX), about $8.7M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Sam Samad has no open-market purchase on record since 2019. Sales in 2 of the 8 years since 2019.
In SEC filings since 2019: no open-market purchase is on record; the latest open-market sale is from 2020.
Illumina, Inc. (ILMN), from 2019 to 2020: 0 purchases and 7 sales.